| Literature DB >> 36040505 |
Esther R McNeill1, James Lucocq2, Kirsty Brown3, Vanessa Kay3.
Abstract
INTRODUCTION AND HYPOTHESIS: During the COVID-19 pandemic, guidance was issued in the United Kingdom advising a delay in routine pessary reviews. The impact of this has not been fully explored. The null hypothesis for this study is that delayed routine pessary reviews during the COVID-19 pandemic did not result in a statistically significant increase in complication rate.Entities:
Keywords: COVID-19 pandemic; Delayed reviews; Pessaries
Year: 2022 PMID: 36040505 PMCID: PMC9426366 DOI: 10.1007/s00192-022-05333-z
Source DB: PubMed Journal: Int Urogynecol J ISSN: 0937-3462 Impact factor: 1.932
Fig. 1Eligibility criteria for pre-pandemic and COVID-19 pandemic groups
Fig. 2Image of different pessary types discussed in this paper
Pessaries by type in the pre-pandemic and COVID-19 pandemic groups
| Pessary | Pre-pandemic (106) | COVID-19 pandemic (125) | |
|---|---|---|---|
| Cube | 13 | 5 | 0.02 |
| Gellhorn | 23 | 26 | 0.87 |
| Shelf | 1 | 12 | 0.005 |
| Ring | 62 | 71 | 0.89 |
| Incontinence dish | 3 | 4 | 0.87 |
| Shaatz | 1 | 4 | 0.24 |
| Donut | 0 | 4 | 0.06 |
Complication rates in the pre-pandemic group
| Pre-pandemic | Cube (13) | Ring (62) | Gellhorn (23) | Shelf (4) | Incontinence dish (3) | Shaatz (1) | All types (106) |
|---|---|---|---|---|---|---|---|
| Bleeding/ulceration/infection | 0 (0%) | 2 (3.2%) | 7 (30.4%) | 0 (0%) | 0 (0%) | 1 (100%) | 10 (9.4%) |
| Other complications | 1 (7.7%) | 9 (14.5%) | 1 (4.3%) | 0 (0%) | 1 (33.3%) | 0 (0%) | 12 (11.3) |
| Removal issues | 0 (0%) | 1 (1.6%) | 4 (17.4%) | 0 (0%) | 0 (0%) | 1 (100%) | 6 (5.7%) |
| Pessary not replaced as a result | 0 (0%) | 1 (1.6%) | 8 (34.8%) | 0 (0%) | 0 (0%) | 0 (0%) | 9 (8.5%) |
Complication rates in the COVID-19 pandemic group
| COVID-19 pandemic | Cube (5) | Ring (71) | Gellhorn (26) | Shelf (12) | Incontinence dish (4) | Shaatz (4) | Donut (3) | All types (125) |
|---|---|---|---|---|---|---|---|---|
| Bleeding/ulceration/infection | 0 (0%) | 11 (15.5%) | 8 (30.8%) | 5 (41.7%) | 1 (25%) | 2 (50%) | 0 (0%) | 27 (21.6%) |
| Other complicationsa | 0 (0%) | 13 (18.3%) | 3 (11.5%) | 2 (16.7%) | 1 (25%) | 1 (25%) | 0 (0%) | 20 (16%) |
| Removal issuesb | 0 (0%) | 3 (4.2%) | 8 (30.8%) | 4 (33.3%) | 0 (0%) | 0 (0%) | 0 (0%) | 15 (12%) |
| Pessary not replaced as result | 0 (0%) | 7 (9.9%) | 4 (15.4%) | 4 (33.3%) | 1 (25%) | 2 (50%) | 0 (0%) | 18 (14.4%) |
aOther complications reported and recorded included: fibrous tissue overgrowth, infection (without associated bleeding), discharge (not investigated as infection), pain/ discomfort, atrophic vaginitis/ erythema and prolapse not controlled/incontinence were not significantly increased.
bRemoval issues: difficulty with the physical removal of the pessary during the check – primarily due to fibrous tissue overgrowth and/or adhesions
Complication rates by sub-type in the pre-pandemic and COVID-19 pandemic groups
| Complications | Pre-pandemic (106) | COVID-19 pandemic (125) | Relative risk (95% CI) | |
|---|---|---|---|---|
| Bleeding/ulceration (moderate to severe) | 9 (8.5%) | 19 (15.2%) | 1.8 (0.9–3.9) | 0.11 |
| Bleeding/ulceration (mild to moderate) | 1 (0.9%) | 8 (6.4%) | 6.8 (0.9–53.3) | 0.03 |
| Fibrous tissue overgrowth | 1 (0.9%) | 2 (1.6%) | 1.8 (0.2–18.4) | 0.66 |
| Infection (without associated bleeding) | 1 (0.9%) | 1 (0.8%) | 0.8 (0.1–13.4) | 0.91 |
| Discharge | 2 (1.9%) | 5 (4%) | 2.1 (0.4–10.7) | 0.35 |
| Pain/discomfort | 1 (0.9%) | 3 (2.4%) | 2.5 (0.3–24.1) | 0.40 |
| Atrophic vaginitis/ erythema | 7 (6.6%) | 10 (12.5%) | 1.2 (0.5–3.1) | 0.69 |
| Prolapse not controlled/incontinent | 4 (3.8%) | 5 (4%) | 1.1 (0.3–3.8) | 0.93 |